Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$2.54 USD
+0.06 (2.42%)
Updated May 30, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANIX 2.54 +0.06(2.42%)
Will ANIX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ANIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIX
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
ANIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
Other News for ANIX
7 Penny Biotech Stocks to Triple Your Investment
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences begins treating fifth patient in ovarian cancer CAR-T trial
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
Anixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccines